Medshine Discovery Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Cstone Pharmaceuticals

Chengdu Jinrui Foundation Biotech Co., Ltd.

Cstone Pharmaceuticals Co., Ltd.

Yanxin Yu

Kevin X Chen

Fang Liu

Zhaoguo Chen

Shuhui Chen

Kai Zhou

Cheng Xie

Boyu Hu

Xinde Chen

Jian Li

Guoping Hu

Xiaofei Wang

Linghui Wu

Xiquan Zhang

Hongjiang Xu

Xin Tian

Xiawei Wei

Xiangjian Wang

Fen Jiang

Xiaoyuan Chen

Jiangfeng Lin

Haomin Chen

Huiyu Zhang

The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof

Disclosed in the present invention are a crystal form of a [1,2,4]triazolo[1,5-c]pyrimidine compound and a preparation method thereof. Further disclosed is a use of the crystal form in the preparation of a medicament for treating Areceptor related diseases. 

Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)

A bicyclic compound acting as a ROR&#x3b3; inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR&#x3b3; inhibitory activities, being expected to be used for treating diseases mediated by ROR&#x3b3; receptors in a mammal. 

Bicylic compound acting as an inhibitor

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors. 

Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors

Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to Areceptor. The R, R, R, ring A, ring B, n, and m are as defined in the specification. 

[1,2,4]triazolo[1,5-c]pyrimidine derivative as Areceptor inhibitor

Growing community of inventors

Shanghai, China

Yanxin Yu